June 2017

Began exporting Lactase to Europe

​

​

March 2017

Acquired Sungwun Bio Co.

​

​

Jan 2017

Awarded patent for mutanase, an oral care enzyme

​

​

July 2016

Recognized as a Global Excellent Company by Daejeon Metropolitan City, KAIST and the University of Texas at Austin

​

​

June 2016

Completed the pilot tests for new lipases for active pharmaceutical ingredient (API) production and biodiesel production

​

​

May 2016

Constructed new production facility at company headquarters in Daejeon to produce specialty enzymes

Food Safety System Certification(FSSC 22000)

​

​

Apr 2016

Completed the pilot test for the world's first bio-retinol production

 
 

Sep 2015

Secured lactase supply contract with Company L

​

​

May 2015

Became publicly traded company listed on KOSDAQ

​

​

Aug 2014

Began production of Katalase S 350L in GenoFocus' Chinese facility

​

​

May 2014

Letter of Understanding and Non Disclosure Agreement Signed with Company L

​

​

Sep 2013

Built plant in Jeonbuk Institute for Bioindustry to produce food enzymes

​

​

Aug 2013

Launched Katalase S 350L for decomposing H2O2 used in semiconductor manufacturing

​

​

May 2012

Established wholly-owned subsidiary in China (GenoFocus Biotechnology Ltd.)

​

​

Dec 2011

Began collaboration with LG Healthcare to develop an oral care enzyme

​

​

Nov 2011

Launched Katalase S for decomposing H2O2 used in textile production

​

​

Oct 2011

Licensed galacto-oligosaccharide synthesis (GOS) production technology to Company Q in China

​

​

Dec 2010

Developed and launched Lactase, ideal for use in GOS mass production

​

​

Nov 2010

Completed production technology for TL Lipase for use in API production

Completed process development for mass production of Catalase

​

​

Sep 2009

Signed NDA with Company I to develop Lactase for GOS mass production usage

​

​

Dec 2008

South Korea's Defense Acquisition Program Administration appointed GenoFocus for a dual use (military and civil) technology development project to produce eco-friendly decontaminants for chemical and biological agents

​

​

Nov 2008

NDA signed with a global pharmaceutical company to optimize lipase for producing next-generation anticonvulsant drugs

​

​

Oct 2004

Dr. Eui-Joong Kim appointed as GenoFocus' CEO

Dr. Jae-Gu Pan becomes GenoFocus' CTO

​

​

Dec 2002

Designated as an INNO-BIZ enterprise

​

​

May 2001

Designated as a National Research Laboratory to develop ‘Microbial Display technology’

​

​

Feb 2001

Certification of Venture Business

​

​

Apr 2000

Incorporated through a KRIBB project by Founder and former CEO and current CTO Dr. Jae-Gu Pan